Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: machine-learning analysis of the DESIRES trial

美罗华 医学 安慰剂 内科学 间质性肺病 胃肠病学 C反应蛋白 肺活量 随机对照试验 事后 析因分析 免疫学 肺 病理 扩散能力 炎症 肺功能 淋巴瘤 替代医学
作者
Ai Kuzumi,Koji Oba,Satoshi Ebata,Kosuke Kashiwabara,Keiko Ueda,Yukari Uemura,Takeyuki Watadani,Takemichi Fukasawa,Shunsuke Miura,Asako Yoshizaki‐Ogawa,Hidenori Kage,Shinichi Sato,Ayumi Yoshizaki
出处
期刊:Rheumatology [Oxford University Press]
卷期号:64 (SI): SI114-SI121 被引量:4
标识
DOI:10.1093/rheumatology/keae716
摘要

OBJECTIVES: Rituximab is emerging as a promising therapeutic option for systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, little is known about factors that predict the efficacy of rituximab in SSc-ILD. METHODS: A post-hoc analysis was performed on prospective data from 48 patients with SSc-ILD in the double-blind, randomized, placebo-controlled DESIRES trial. A total of 28 baseline factors were selected as candidates to predict the efficacy of rituximab on the percentage of predicted forced vital capacity (ppFVC) at 24 weeks. A machine learning causal tree algorithm was used to explore the combination of predictors to identify subpopulations with a good response to rituximab. RESULTS: Serum levels of C-reactive protein (CRP) and Krebs von den Lungen-6 (KL-6) were selected as branches of the decision tree to stratify patients into three subpopulations. In the subpopulation with serum CRP levels ≥0.055 mg/dl, ΔppFVC was significantly higher in the rituximab group than in the placebo group [difference 8.01% (95% CI: 4.40%, 11.62%)]. In the subpopulation with serum CRP levels <0.055 mg/dl and serum KL-6 levels ≥364 U/ml, ΔppFVC was comparable between the two groups [difference 2.47% (95% CI: -1.99%, 6.92%)]. In the subpopulation with serum CRP levels <0.055 mg/dl and serum KL-6 levels <364 U/ml, ΔppFVC was significantly lower in rituximab than in placebo [difference -6.85% (95% CI: -10.80%, -2.91%)]. CONCLUSION: Even slight elevations in serum CRP levels are associated with the improvement in ppFVC and may serve as predictors of rituximab efficacy in SSc-ILD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xu发布了新的文献求助10
刚刚
zzzzzzzz发布了新的文献求助10
刚刚
科研通AI6.4的应助被嘿嘿采纳,获得10
1秒前
荒1完成签到,获得积分10
1秒前
隐形曼青的应助被LamlamC采纳,获得10
1秒前
英俊的铭的应助被焦恩俊采纳,获得10
1秒前
1秒前
英姑的应助被是述不是沭采纳,获得10
1秒前
直率曼荷完成签到,获得积分10
2秒前
3秒前
3秒前
LDX发布了新的文献求助10
3秒前
4秒前
ycy发布了新的文献求助10
4秒前
4秒前
4秒前
FashionBoy的应助被小少采纳,获得10
4秒前
4秒前
最饿身重完成签到,获得积分10
4秒前
molihuakai的应助被Ryan采纳,获得30
5秒前
pluto的应助被水电费采纳,获得10
5秒前
5秒前
卢111完成签到,获得积分20
5秒前
heluoyu完成签到,获得积分10
5秒前
5秒前
luluyang完成签到 ,获得积分10
6秒前
FashionBoy的应助被早日发文章采纳,获得10
6秒前
可爱的函函的应助被123采纳,获得10
6秒前
风中人杰完成签到,获得积分10
6秒前
可爱的函函的应助被威威采纳,获得10
6秒前
星辰大海的应助被洋洋洋采纳,获得10
7秒前
突突突兔完成签到,获得积分10
7秒前
7秒前
Len发布了新的文献求助10
8秒前
8秒前
欣慰若发布了新的文献求助10
8秒前
心灵美复天完成签到,获得积分10
8秒前
8秒前
小谢关注了科研通微信公众号
8秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162138
求助须知:如何正确求助?哪些是违规求助? 9556501
关于积分的说明 21735379
捐赠科研通 7752349
什么是DOI,文献DOI怎么找? 3427639
关于科研通互助平台的介绍 2552678
邀请新用户注册赠送积分活动 2472242